Sware’s cloud-based platform features an open API architecture. Credit: LALAKA / Shutterstock.

Sware has secured $6m in a Series B funding round for expediting life sciences innovation by automating US Food and Drug Administration-mandated software validation.

The investment, led by First Analysis, will accelerate the development of Sware’s Res_Q computer systems validation platform for streamlining processes with AI, and expand its sales team.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Sware has raised a total of $26m since its inception, with contributions from LRVHealth, New Stack Ventures, and Insight Partners.

Developed to address the challenges of validation debt in the life sciences sector, the Res_Q platform is designed to integrate and scale validation efforts across IT, manufacturing, and laboratory systems.

The cloud-based platform offers a comprehensive solution for medical device, pharmaceutical and biotechnology companies to automate, integrate and scale for managing their validation processes.

See Also:

It features an open API architecture, as well as intelligent risk assessments to initiate workflows and assign workloads based on risk profiles.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Sware CEO Ellen Reilly said: “Every time a life sciences company adopts a new technology or every time technology vendors update products, validation requirements add time and unforeseen expenses that only compound as products move towards commercialisation. Automating these processes is the only way to eliminate this validation debt.

“We have deep experience helping life sciences companies through these processes and we’ve built everything we’ve learned into the Res_Q platform. This funding will enable us to scale the impact we’re making towards eliminating validation debt and to continue innovating with AI-driven capabilities for even smoother automation.”

First Analysis managing director Matt Nicklin will join the Sware board of directors as part of the investment agreement.